-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11

Benzinga·05/20/2026 12:34:32
Listen to the news
Jefferies analyst Roger Song initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $11.